Product Details
| Product Name:
Pivanex |
CAS No.:
122110-53-6 |
| Purity:
≥98% |
Supply Ability:
10g |
| Release date:
2025/07/25 |
Product Introduction
Bioactivity
| Name | Pivanex |
| Description | Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis. |
| In vitro | Pivanex has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Pivanex (200 μM) causes enhancement in the G2-M phase, moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle. Pivanex (100-500 μM) shows significant anti-proliferation activity in K562 cells. Pivanex (100-500 μM) also increases apoptosis and caspase activity in K562 cells [1][2]. |
| In vivo | Pivanex treatment also marked delays in the end stage of disease as defined by the onset of body mass loss. Pivanex (200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice [3]. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (494.44 mM), Sonication is recommended.
|
| Keywords | spinal | Pivanex | Pivalyloxymethyl Butyrate | NSCLC | myelogenous | muscular | lymphoblastic | lung | leukemia | K562 | Inhibitor | inhibit | Histone deacetylases | HDAC | CML | Chronic | cancer | Bcr-Abl | BcrAbl | atrophy | Apoptosis | AN9 | AN 9 | ALL | Acute |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Acetylcysteine | L-Glutamic acid monosodium salt monohydrate | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | Valproic Acid | Curcumin | L-Ascorbic acid sodium salt | Alginic acid |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1228439-71-1
$117.00 / 1mg
-
CAS:176975-26-1
$160.00 / 1mg
-
CAS:1354744-91-4
$40.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States